Table 2.

Patient characteristics and CD123 expression of primary AML patient samples

AML sample ID	Age/sex	Cytogenetics	Flt3 mutational status	Clinical status at time of sample collection	Sample type	CD123 (RFI)*	CD123% positive†
179	74/M	Intermediate risk, t(1;7), t(14;15)	ND	Relapsed	PB	428.32	99.22
373	47/M	Poor risk, complex abnormalities in 3 cell lines	ND	Relapsed	PB	1052.83	99.66
493	46/F	Intermediate risk, trisomy 8	ND	Relapsed	PB	23.98	76.80
519	44/F	del(17p), dic (11;7), clonal loss of TP53/17p13.1	ND	Relapsed	PB	63.18	97.40
545	58/M	Intermediate risk, t(3;6), del(7)	ND	Induction failure	PB	52.73	99.32
559	59/M	Complex abnormalities, massive hyperdiploidy	Negative	Relapsed	Apheresis	9.30	45.0
605	55/M	Normal	Negative	Persistent	PB	58.48	99.91
722	22/M	Intermediate risk, t(14;21), del(9q)	Negative	Untreated	PB	33.53	92.74
813	48/F	Complex abnormalities, trisomy 8, trisomy 21, add(17)	ND	Untreated	PB	37.19	90.93

F, female; M, male; ND, not determined; PB, peripheral blood.

^*RFI is the ratio of the median of the anti-CD123 antibody (clone 9F5)-stained signal to isotype-matched control stain in the CD34⁺ population.

^†Gated on CD34⁺ population.